The Lancet Oncology

Journal

Publication Venue For

  • Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.  23:e374-e384. 2022
  • Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.  23:149-160. 2022
  • Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.  22:1103-1114. 2021
  • Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.  22:727-736. 2021
  • Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.  22:609-619. 2021
  • Global access to medical imaging and nuclear medicine.  22:425-426. 2021
  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.  22:e105-e118. 2021
  • Treatments for newly diagnosed multiple myeloma: when endurance is interrupted.  21:e540. 2020
  • Sebaceous carcinoma: evidence-based clinical practice guidelines.  20:e699-e714. 2019
  • The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017.  20:1211-1225. 2019
  • Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study.  20:998-1010. 2019
  • Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.  20:862-876. 2019
  • Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.  20:e29-e41. 2019
  • Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.  19:1192-1204. 2018
  • Timing of androgen-deprivation therapy in prostate cancer.  18:e634. 2017
  • Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.  18:1373-1385. 2017
  • A step towards predicting checkpoint inhibitor response in kidney cancer.  18:982-983. 2017
  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study.  18:1061-1075. 2017
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.  18:42-51. 2017
  • HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.  17:1435-1444. 2016
  • Cachexia in patients with cancer.  17:e220. 2016
  • The US Cancer Moonshot initiative.  17:e178-e180. 2016
  • Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.  17:484-495. 2016
  • Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study.  16:1025-1036. 2015
  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.  15:1100-1108. 2014
  • Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.  15:1513-1520. 2014
  • RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1.  15:1469-1480. 2014
  • Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: A phase 3, open-label, randomised trial.  14:1326-1336. 2013
  • Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.  14. 2013
  • Subsequent neoplasms of the CNS among survivors of childhood cancer: A systematic review.  14. 2013
  • Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.  13:100-110. 2012
  • Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.  11:21-28. 2010
  • Translating biological insights into clinical endpoints in neuro-oncology.  10:928-929. 2009
  • Preserving function and quality of life after thyroid and parathyroid surgery.  9:1069-1075. 2008
  • Nomograms as clinicobiological predictors of survival in glioblastoma.  9:5-6. 2008
  • Diet, exercise, and complementary therapies after primary treatment for cancer.  7:1017-1026. 2006
  • Genomics-based hypothesis generation: A novel approach to unravelling drug resistance in brain tumours?.  5:89-100. 2004
  • Predicting outcome and tailoring treatment in high-grade gliomas.  4:269-270. 2003
  • Management of terminal cancer in elderly patients.  4:149-157. 2003
  • Brain-tumour drug resistance: The bare essentials.  3:397-406. 2002
  • International Standard Serial Number (issn)

  • 1470-2045
  • Electronic International Standard Serial Number (eissn)

  • 1474-5488